Loading
A phase 2 trial of Shark cartilage in Multiple myeloma, run by AEterna Zentaris, completed.
AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT00022282 by AEterna Zentaris, started 2001-04 and reaching its primary completion in 2007-03. Interventions recorded: shark cartilage extract AE-941. Conditions recorded: Multiple Myeloma and Plasma Cell Neoplasm.
Linked to the technology Shark cartilage because the registry names it ("shark cartilage") among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Shark cartilage (AE-941, Neovastat) and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/